SCM
CDIO icon

Saba Capital Management’s Cardio Diagnostics CDIO Stock Holding History

Saba Capital Management’s Portfolio CDIO Stock Details CDIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,710
Closed -$4.73M – 926
2022
Q3 		$4.73M Hold
15,710
– – 0.05% 534
2022
Q2 		$4.69M Hold
15,710
– – 0.05% 537
2022
Q1 		$4.66M Buy
+15,710
New +$4.64M 0.07% 450

Other funds holding CDIO

LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Saba Capital Management's CDIO Position: Q4 2022 in Review

Saba Capital Management sold out of Cardio Diagnostics (CDIO) in Q4 2022, closing a stake of 15,710 shares — an estimated $4.73M sold.

Saba Capital Management first reported a position in CDIO in Q1 2022 and held it in 3 quarters. The position peaked at $4.73M in Q3 2022. 11 funds tracked by Wall St. Rank hold CDIO as of Q4 2022.

  • Saba Capital Management reported no remaining Cardio Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Saba Capital Management sold 15,710 Cardio Diagnostics shares in Q4 2022, an estimated $4.73M.
  • Saba Capital Management first reported a position in Cardio Diagnostics in Q1 2022 and held it in 3 quarters.
  • Saba Capital Management's Cardio Diagnostics position peaked at $4.73M in Q3 2022.
  • 11 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q4 2022.

Based on Saba Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.